January 31, 2015 7:11 AM ET


Company Overview of Cougar Biotechnology, Inc.

Company Overview

Cougar Biotechnology, Inc., a development stage biopharmaceutical company, engages in the development and in-license of clinical stage drugs in the field of oncology. Its portfolio includes CB7630, a targeted inhibitor of 17alpha-hydroxylase/c17 and 20 lyase enzyme, which is used as second-line hormonal therapy for patients with castration-resistant prostate cancer and breast cancer in North America, Europe, and Australia; CB3304, a microtubule targeting agent that alters microtubule dynamics, blocks mitosis, and causes apoptosis; and CB1089, an analog of vitamin D, which is used for the treatment of prostate, breast, pancreas, colon, skin, and brain tumors. The company was founded in 2003 a...

Mailstop E1756

920 Route 202

Raritan, NJ 08869

United States

Founded in 2003

54 Employees

Key Executives for Cougar Biotechnology, Inc.

Director of Investor Relations
Vice President of Clinical Research and Development
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Exeltis USA Dermatology, LLC United States
A&Z Pharmaceutical, Inc. United States
Biovax, Inc. United States
King Bio, Inc. United States
Merck Sharp & Dohme Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cougar Biotechnology, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.